A recently-announced partnership between two US firms is designed to further artificial pancreas research. Maryland-based Senseonics is developing a subcutaneous continuous glucose monitor (CGM) the size of a pill, part of its Eversense System. It automatically transmits readings to a mobile app for up to 90 days.
The agreement aims to integrate monitor data with the inControl diabetes management software from TypeZero Technologies, located in neighboring Virginia. The readings will enable TypeZero’s artificial pancreas algorithms to control a user’s insulin pump. The combination also can indicate dosage for insulin pen users. Other advantages include the sensor’s small size and life expectancy, far longer than the five to seven days of existing systems.
TypeZero CEO Chad Rogers explains in a press release that “integrating our inControl platform with the reliable and durable Eversense CGM System…could give patients yet another tool for managing their health and simplifying their lives.”